P/E ratio for NanoViricides (NNVC)
P/E ratio as of April 2024 (TTM): -1.99
According to NanoViricides's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.99153. At the end of 2022 the company had a P/E ratio of -1.85.
P/E ratio history for NanoViricides from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.85 | -61.71% |
| 2021 | -4.83 | 172.7% |
| 2020 | -1.77 | 46.81% |
| 2019 | -1.21 | -33.33% |
| 2018 | -1.81 | -67.09% |
| 2017 | -5.50 | 2.8% |
| 2016 | -5.35 | -57.2% |
| 2015 | -12.5 | -40.26% |
| 2014 | -20.9 | 26.41% |
| 2013 | -16.6 | 86.14% |
| 2012 | -8.89 | -34.44% |
| 2011 | -13.6 | -53.87% |
| 2010 | -29.4 | 3.76% |
| 2009 | -28.3 | -9.05% |
| 2008 | -31.2 | 165.14% |
| 2007 | -11.8 | -36.49% |
| 2006 | -18.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 15.1 | -856.73% | 🇺🇸 USA |
 Merck MRK | 68.7 | -3,551.83% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.2 | -710.90% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.2 | -663.27% | 🇬🇧 UK |
 Novavax NVAX | -0.5410 | -72.83% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -3.60 | 80.77% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.